4,960 Shares in Global Blood Therapeutics Inc (GBT) Acquired by Neuburgh Advisers LLC

Share on StockTwits

Neuburgh Advisers LLC purchased a new stake in Global Blood Therapeutics Inc (NASDAQ:GBT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 4,960 shares of the company’s stock, valued at approximately $204,000.

Other hedge funds have also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its position in Global Blood Therapeutics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 236,471 shares of the company’s stock valued at $10,689,000 after purchasing an additional 15,211 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Global Blood Therapeutics by 60.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 40,034 shares of the company’s stock worth $1,521,000 after acquiring an additional 15,037 shares in the last quarter. Cambridge Investment Research Advisors Inc. raised its position in shares of Global Blood Therapeutics by 29.3% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 6,855 shares of the company’s stock worth $260,000 after acquiring an additional 1,555 shares in the last quarter. Candriam Luxembourg S.C.A. raised its position in shares of Global Blood Therapeutics by 80.2% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 164,000 shares of the company’s stock worth $6,232,000 after acquiring an additional 73,000 shares in the last quarter. Finally, Swiss National Bank raised its position in shares of Global Blood Therapeutics by 8.7% during the 3rd quarter. Swiss National Bank now owns 85,900 shares of the company’s stock worth $3,264,000 after acquiring an additional 6,900 shares in the last quarter.

GBT has been the topic of several research analyst reports. Wedbush reissued a “buy” rating and set a $73.00 target price on shares of Global Blood Therapeutics in a research report on Monday, November 19th. HC Wainwright reissued a “buy” rating and set a $150.00 target price on shares of Global Blood Therapeutics in a research report on Wednesday, November 28th. BidaskClub lowered Global Blood Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, November 30th. Oppenheimer set a $82.00 target price on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 3rd. Finally, Cantor Fitzgerald set a $96.00 target price on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Monday, December 3rd. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Global Blood Therapeutics currently has a consensus rating of “Buy” and an average target price of $85.79.

NASDAQ:GBT opened at $52.62 on Monday. The company has a market cap of $2.96 billion, a P/E ratio of -15.43 and a beta of 2.13. Global Blood Therapeutics Inc has a 52-week low of $30.15 and a 52-week high of $54.88.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings results on Wednesday, February 27th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.04). During the same period in the previous year, the firm posted ($0.95) earnings per share. As a group, analysts expect that Global Blood Therapeutics Inc will post -3.89 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “4,960 Shares in Global Blood Therapeutics Inc (GBT) Acquired by Neuburgh Advisers LLC” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://weekherald.com/2019/03/18/4960-shares-in-global-blood-therapeutics-inc-gbt-acquired-by-neuburgh-advisers-llc.html.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Featured Story: Options Trading – What is a Straddle?

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.